First line drugs in chronic stable effort angina--the case for newer, longer-acting calcium channel blocking agents

Area of Science:

• Cardiology
• Pharmacology

Background:

• Current guidelines recommend beta-adrenergic blocking agents as first-line treatment for chronic stable effort angina.
• This recommendation is based on established evidence, but newer data may warrant a reassessment.

Purpose of the Study:

• To critically re-examine the evidence for calcium channel blocking agents (CCBs) in managing chronic stable angina.
• To evaluate safety, side-effects, tolerability, and mortality data, particularly for newer CCB generations.

Main Methods:

• Review of newly available and potentially overlooked evidence not cited by current guidelines.
• Inclusion of recent clinical trials and a meta-analysis of placebo-controlled trials on long-acting CCBs.
• Evaluation of safety, tolerability, and mortality data.

Main Results:

• Newer, longer-acting, second-generation CCBs demonstrate good tolerability and benefits in hypertension.
• Verapamil, an older CCB, is highlighted for its safety and efficacy.
• Dihydropyridine CCBs and beta-blockers show similar effectiveness in angina associated with hypertension, particularly in the elderly.
• Beta-blockers can have undesirable side effects like impotence and reduced exercise capacity.

Conclusions:

• The current recommendation for first-line beta-blockers for chronic stable angina may need reconsideration.
• CCBs, especially newer formulations and verapamil, present a strong alternative with favorable safety and efficacy profiles.
• Individual patient needs and pathophysiology should guide the choice between beta-blockers and CCBs.